Neurotrials Research, Inc.

Founded in 1997 and based in Atlanta, US, Neurotrials Research, Inc. conducts clinical research studies focused on neurological conditions, providing essential data for the advancement of therapies targeting diseases such as Alzheimer’s, multiple sclerosis, and Parkinson’s. NeuroTrials Research, Inc. specializes in clinical research for various neurological conditions.

Founded in 1997 in Atlanta, US, the company has maintained its focus on advancing understanding and treatment of neurological disorders. The firm has not undergone any significant pivots in its business strategy. It was established by professionals in the field, though specific founders are not mentioned. NeuroTrials Research specializes in conducting clinical research studies focused on various neurological conditions, including but not limited to Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.

Their core offerings encompass both Phase I-IV clinical trials, which involve testing new therapies and drugs for safety and efficacy, and observational studies that analyze ongoing disease progression and treatment responses. These research services aim to advance the understanding of neurological disorders and improve treatment options for patients. NeuroTrials Research caters to pharmaceutical and biotech companies looking to develop innovative therapies by providing a robust platform for rigorous clinical testing. The firm operates primarily within the United States, engaging with clients across the pharmaceutical and healthcare sectors to deliver comprehensive research solutions.

NeuroTrials Research generates revenue through various business transactions structured around clinical trial services. The company engages in B2B partnerships with pharmaceutical and biotechnology firms that require extensive clinical research to support their drug development initiatives. Revenue is primarily derived from contract agreements that may encompass fixed fees for specific studies, milestone payments based on trial progress, and potential success-based royalties. These transactions are designed to align the interests of NeuroTrials Research with its clients, ensuring collaborative efforts in advancing treatment options.

While specific financial figures are undisclosed, the company's revenue is fundamentally linked to the successful execution of clinical trials and the delivery of reliable data to clients, thereby fostering long-term relationships within the healthcare research ecosystem. In January 2026, Conquest Research, LLC, a portfolio company of Reynolda Equity Partners, acquired Neurotrials Research, Inc.